Search

Your search keyword '"Galetta, D."' showing total 56 results

Search Constraints

Start Over You searched for: Author "Galetta, D." Remove constraint Author: "Galetta, D." Publisher elsevier ltd Remove constraint Publisher: elsevier ltd
56 results on '"Galetta, D."'

Search Results

1. MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database

3. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

4. LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study

10. 2001P Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy

12. RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients

14. 1019P Pattern of clinical activity of anticancer vaccine OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial

16. LBA47 Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial

17. 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial

22. 1518P - Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real-world data from a European Cohort with focus on subgroups of interest

28. E11 - The close link between anxiety and cluster symptoms in lung cancer patients during first-line chemotherapy: further data from a dedicated WALCE (Women Against Lung Cancer in Europe) survey

30. E2 - ASTRIS, a real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC): preliminary analysis of the Italian cohort

32. 1235P - Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)

35. A21 - Chemotherapy-induced nausea and vomiting (CINV) in patients with stage III/IV lung cancer during the first-line treatment: assessment by physician, nurse and patient. Preliminary results from an Italian multicenter survey

38. A03* - Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)

44. 1278P - Be-Positive: Beyond Progression After Tyrosine Kinase Inhibitor in Egfr-Positive Non-Small Cell Lung Cancer (Nsclc) Patients. Preliminary Results from a Multicenter Italian Observational Study

Catalog

Books, media, physical & digital resources